Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2002

View Archived Issues

Dual inhibitor of ECE-1 and NEP demonstrates efficacy in preclinical studies

Partaject-delivered busulfan granted orphan drug status

Quick-Med licenses technologies from U. of Florida

The antisense oligonucleotide oblimersen sodium a highlight of the ASH meeting

Novel agents for ischemic conditions identified by Galileo researchers

GSK presents several series of urotensin-II antagonists

Fujisawa and Daiso present novel compounds with apo B secretion-inhibitory activity

VEGFR inhibitors and their use in psoriasis and other disorders

Bayer presents new thyroid hormone-like compounds for use in arteriosclerosis therapy

Safety restrictions announced for Eprex/Erypo in patients with chronic renal failure

GenVec and Fuso collaborate to develop targeted cancer therapy candidate

Athersys and U. of Minnesota to develop adult stem cell technology

Cell Genesys and VectorLogics collaborate on second-generation oncolytic virus therapies

Corus-1020 completes phase I study

VEGF gene transfer evaluated for diabetic neuropathy in NIH-funded trial

U. of Arkansas to assess CEL-1000 against Chlamydia

Efficacy of bortezomib in hematological malignancies

Tempostatin enters phase II trial for recurring bladder cancer

IDEC-114 reported safe and effective in refractory follicular lymphoma

New data on bryostatin 1 combined with fludarabine in CLL

No objective antitumor responses in AML patients treated with PTK-787/ZK-222584

Disappointing phase III preliminary results for CeaVac in colorectal cancer

AP-158 kills mupirocin-resistant bacteria in vivo

Merck & Co. plans growth in 2003 on two fronts

Oxime tachykinin antagonist with oral activity and potential as an asthma therapy

Merck KGaA announces name changes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...